Stage I Colon Cancer
10
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
20.0%
2 terminated out of 10 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer
Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer